Viking Therapeutics Obesity Drug Shows Promise, Could Rival Leaders Novo Nordisk and Eli Lilly
-
Viking Therapeutics' drug VK2735 showed promising results for treating obesity in a phase 2 trial, with greater weight loss than competitors in a short 13-week trial period.
-
VK2735 could be more effective than Novo Nordisk's Wegovy and Eli Lilly's Zepbound for weight loss when used long-term. More trial data expected in Q2 2022.
-
Viking has funding to support VK2735's further development. The obesity treatment market has room for multiple blockbuster drugs.
-
Novo Nordisk and Eli Lilly have strong obesity drug sales, pipelines and upside still for investors.
-
Viking Therapeutics has upside if VK2735 trial data continues to impress, though risks remain as a pre-revenue biotech stock.